Aboleris Pharma
ID: 12873981AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.
3
Funding Rounds
$61.0m
Money raised
Recent Funding Rounds
Overview
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.
- Website:
- Business model: B2B
- Headquarters: Nantes
- Social accounts: linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Funding
Funding series
Funding Series Analysis
The company Aboleris Pharma has raised a total of $61m in funding over 3 rounds.
Key Insights:
- AbolerIS Pharma September 2023 Series A Funding Round: $29m
- AbolerIS Pharma September 2023 Series A Funding Round: $29m
- AbolerIS Pharma November 2020 Seed Funding Round: $3m
Industries
Aboleris Pharma is active in the following industries: